Videos

Video: Re-energise your kinase discovery programme

9 June 2021

Using Promega’s NanoBRET technology, scientists at Aurelia Bioscience have implemented intracellular kinase assays designed to study the interaction of compounds on kinase targets in intact living cells. Advantages of this technique include examination of compound binding to target kinases at physiological ATP concentrations, expression of full-length kinase target in cells, disruption of cells (with digitonin) […]

C. elegans: a natural model for developing therapies to slow ageing

11 May 2021

Ageing is a complex and heterogeneous process and is best studied using natural models of ageing in whole organisms and large test populations. C. elegans is a proven model in many fields of biology including ageing, where major breakthroughs have occurred by identifying mutants and interventions that increase lifespan. To evaluate and develop therapies that […]

Meet Ulysses, the fully automated drug discovery platform

6 April 2021

Welcome to the Future of Drug Discovery. Welcome to Arctoris from Arctoris on Vimeo. Arctoris is a global platform company headquartered in Oxford, UK that is transforming drug discovery by combining robotics and AI. Arctoris developed and operates Ulysses, a fully automated drug discovery platform. Ulysses has been created to address fundamental problems with conventional […]

NanoBRET technology enables the study of the interaction of compounds

1 April 2021

Aurelia Bioscience is a pre-clinical contract research organisation specialising in bioassay development, pharmacological profiling and compound screening. Scientists at Aurelia Bioscience have experience developing new and innovative bio-assays for different target classes using technologies to deliver client projects in a timely, efficient and cost-effective manner. Using Promega’s NanoBRET technology, Aurelia Bioscience has implemented intracellular kinase […]

CAR T-cell therapy highly effective in patients with high-risk non-Hodgkin lymphoma

8 December 2020

A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a Phase III clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting. While NHL tends to be a slow-growing disease, […]

Scientists use geometry to track cell migrations with potential impact for cancer research

4 December 2020

  Cells are constantly moving throughout our bodies, performing functions crucial to tissue development, immune responses and general wellbeing. This locomotion—an essential feature of biological processes, both normal and pathological—is guided by chemical cues long studied by scientists interested in cellular migration. But a team of physicists and biologists at UC San Diego and UC […]

Watch now: COVID Moonshot – Data Coordination Strategy by Dr. Lizbe Koekemoer

2 December 2020

The COVID Moonshot is a global consortium that aims to rapidly develop antivirals for COVID-19. Dr. Lizbe Koekemoer of Oxford University describes how the project team leverages the CDD Vault informatics platform to effectively store, manage, and share data among multiple international partners.